How many FDA actions does Argus HQ track for Dabur India Limited?

15 total: 0 warning letters, 14 recalls, 0 approval records, and 1 Form 483 inspection citation.

What is the most recent FDA action on file for Dabur India Limited?

June 24, 2026. Argus HQ ingests new FDA enforcement records daily.

Has Dabur India Limited had product recalls?

Yes, 14 recalls on file. See the full history below for each one.

Is this FDA enforcement data for Dabur India Limited official?

Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

Dabur India Limited — FDA Compliance Timeline

Here's the summary: Argus HQ has recorded 14 FDA events for Dabur India Limited: 0 warning letters, 14 recalls, 0 approvals, and 0 inspection 483 observations. These events span from 2026-06-24 to 2026-06-24. The most severe rating Argus HQ has assigned across this history is "high". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

FDA action counts

Total FDA actions	15
Warning letters	0
Recalls	14
Approval records	0
Form 483 inspection citations	1
Most recent action	June 24, 2026

Enforcement history

On 2026-06-24, Argus HQ recorded a FDA recall for Dabur India Limited, rated "high" severity in Argus HQ's classification: Dabur India Limited — Class II recall: Med Pride, HYDROCORTISONE CREAM 1%, Net Wt. 1 oz (28.3g) tubes, Manufactured for… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-06-24, Argus HQ recorded a FDA recall for Dabur India Limited, rated "high" severity in Argus HQ's classification: Dabur India Limited — Class II recall: Rapidol, Triple Antibiotic First Aid Ointment, Bacitracin Zinc 400 units, Neomyc… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-06-24, Argus HQ recorded a FDA recall for Dabur India Limited, rated "high" severity in Argus HQ's classification: Dabur India Limited — Class II recall: Med Pride, Triple Antibiotic Ointment, Bacitracin Zinc (equivalent to 400 units)… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-06-24, Argus HQ recorded a FDA recall for Dabur India Limited, rated "high" severity in Argus HQ's classification: Dabur India Limited — Class II recall: Lucky Super Soft, First Aid Triple Antibiotic Ointment, Bacitracin zinc 400 unit… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-06-24, Argus HQ recorded a FDA recall for Dabur India Limited, rated "high" severity in Argus HQ's classification: Dabur India Limited — Class II recall: Med Pride, Bacitracin Zinc Ointment, 1oz (28.3g) per tube, 72 tubes per case, Ma… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-06-24, Argus HQ recorded a FDA recall for Dabur India Limited, rated "high" severity in Argus HQ's classification: Dabur India Limited — Class II recall: Lucky Super Soft, Antifungal Athlete's Foot Cream, Clotrimazole 1% Cream, Net Wt… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-06-24, Argus HQ recorded a FDA recall for Dabur India Limited, rated "high" severity in Argus HQ's classification: Dabur India Limited — Class II recall: Med Pride, HYDROCORTISONE CREAM 1%, Net Wt. 16oz (454g) tubes, Manufactured for:… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-06-24, Argus HQ recorded a FDA recall for Dabur India Limited, rated "high" severity in Argus HQ's classification: Dabur India Limited — Class II recall: Med Pride, Bacitracin Zinc Ointment, 500 units, 1oz (28.3g) tubes, Manufactured… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On 2026-06-24, Argus HQ recorded a FDA recall for Dabur India Limited, rated "high" severity in Argus HQ's classification: Dabur India Limited — Class II recall: Lil Drug Store, Triple Antibiotic Ointment, Bacitracin Zinc (400 units), Neomyci… An FDA recall record reflects a firm removing or correcting a product already in distribution because it does not meet FDA requirements. On.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Dabur India Limited has 14 separate FDA recalls on file, more than a single isolated recall event. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event.

Frequently asked questions

How many FDA actions does Argus HQ track for Dabur India Limited?: 15 total: 0 warning letters, 14 recalls, 0 approval records, and 1 Form 483 inspection citation.
What is the most recent FDA action on file for Dabur India Limited?: June 24, 2026. Argus HQ ingests new FDA enforcement records daily.
Has Dabur India Limited had product recalls?: Yes, 14 recalls on file. See the full history below for each one.
Is this FDA enforcement data for Dabur India Limited official?: Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). Dabur India Limited — FDA Compliance Timeline. Digital Empire LLC. Retrieved from https://argushq.ai/company/dabur-india-limited

MLA

"Dabur India Limited — FDA Compliance Timeline." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/company/dabur-india-limited.

Chicago

Argus HQ Research. "Dabur India Limited — FDA Compliance Timeline." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/company/dabur-india-limited.

BibTeX

@misc{argushq_argushq_ai_company_dabur_india_limited_2026,
  title = {Dabur India Limited — FDA Compliance Timeline},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/company/dabur-india-limited},
  note = {Accessed: July 13, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗